Why GRAIL Stock Is Back in Focus After the Galleri FDA Panel DateGRAIL (GRAL) is drawing fresh attention after regulators set a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. The Galleri…This story appeared on finance.yahoo.com , 2026-08-08 05:12:29.